tiprankstipranks
Trending News
More News >

Portfolio #1 - New Portfolio

Portfolio #1
Individual Investor
Ranked #462,014 out of 806,884 TipRanks' Investors
Success Rate
31%
171 out of 558
profitable transactions
Average Return
20.95%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▲ 1.80%
6-Month Return▲ 4.28%
12-Month Return▲ 12.37%
YTD Return▲ 7.72%
Total Return▲ 193.43%

Best Trade

Opened at
Closed at-
Gain▲ 6009.65%

Bio

General portfolio. I have a private one which I am more active in

Performance

12.86%0-12.86%
▲ 5.10%
▼ 2.41%
▼ 4.28%
Dec 2024
▲ 6.03%
▲ 2.69%
▲ 4.74%
Jan 2025
▼ 12.86%
▼ 1.27%
▼ 6.01%
Feb 2025
▼ 1.80%
▼ 5.57%
▼ 9.16%
Mar 2025
▲ 1.84%
▼ 0.87%
▲ 6.36%
Apr 2025
▲ 12.20%
▲ 6.28%
▲ 4.90%
May 2025
▲ 6.24%
▲ 5.14%
▲ 6.06%
Jun 2025
▲ 1.29%
▲ 0.46%
▲ 1.79%
Jul 2025
TipRanks AverageS&P 500Investor Portfolio
▲ 5.10%▼ 2.41%▼ 4.28%
▲ 6.03%▲ 2.69%▲ 4.74%
▼ 12.86%▼ 1.27%▼ 6.01%
▼ 1.80%▼ 5.57%▼ 9.16%
▲ 1.84%▼ 0.87%▲ 6.36%
▲ 12.20%▲ 6.28%▲ 4.90%
▲ 6.24%▲ 5.14%▲ 6.06%
▲ 1.29%▲ 0.46%▲ 1.79%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Kineta
▼ 99.92%
2
Close
Jun 30, 2025
Inozyme Pharma
▼ 17.70%
2
Close
Jun 30, 2025
TuHURA Biosciences
0%
▲ 7.62%
1
Open
Jun 30, 2025
Checkpoint Therapeutics
▼ 81.72%
2
Close
May 29, 2025
DermTech
0%
0.00%
1
Open
May 22, 2025
Ascendant Resources Inc
▼ 70.59%
2
Close
May 21, 2025
Vincerx Pharma Inc
▼ 99.91%
2
Close
Apr 17, 2025
Intra-Cellular Therapies
▲ 79.10%
2
Close
Apr 01, 2025
Marchex
▼ 5.28%
2
Close
Mar 07, 2025
Atricure
0%
▼ 17.48%
1
Open
Feb 18, 2025
Innovid
▼ 23.60%
2
Close
Feb 12, 2025
Softbank
0%
▲ 11.22%
1
Open
Feb 06, 2025
Revance Therapeutics
▼ 84.47%
2
Close
Feb 05, 2025
Adevinta ASA
▼ 8.65%
2
Close
Jan 21, 2025
UnitedHealth
0%
▼ 41.49%
1
Open
Jan 21, 2025
VBI Vaccines
▼ 99.99%
2
Close
Jan 13, 2025
Fission Uranium
▲ 7.23%
2
Close
Dec 24, 2024
Paladin Energy Ltd
0.01%
▲ 6.92%
1
Open
Dec 24, 2024
Bellerophon
▼ 71.88%
4
Close
Dec 18, 2024
TFF Pharmaceuticals
▼ 99.96%
2
Close
Dec 12, 2024